Latest Safety News

HighCom Limited appoints seasoned executive Geoffrey Knox as Executive Chairman and CEO, signaling a strategic push to strengthen its defence manufacturing and sustainment operations in Australia and the US.

Racura Oncology has launched a strategic collaboration with Emory University to investigate (E,E)-bisantrene’s potential to overcome resistance to osimertinib in EGFR-mutated non-small cell lung cancer. This partnership aims to bolster Racura’s HARNESS-1 clinical trial and strengthen its position in the competitive lung cancer treatment landscape.

Monadelphous Group Limited has landed a significant five-year maintenance contract with Rio Tinto, reinforcing its long-standing presence in the Pilbara iron ore operations.

OzAurum Resources has reported promising assay results from its James Stage 1 open pit drilling at Mulgabbie North, confirming consistent shallow high-grade gold mineralisation and supporting a near-term, low-cost heap leach development strategy.

Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.

DPM Metals has once again met its gold production guidance for 2025, marking eleven consecutive years of hitting targets, while preparing for a significant ramp-up at its Vareš operation.

Entropy Neurodynamics reports compelling Phase 2a results showing oral psilocybin dramatically reduces binge eating episodes and related psychiatric symptoms, supporting advancement of its lead IV psilocin candidate.

Firebird Metals has commissioned its proprietary equipment for producing advanced lithium-manganese-rich cathode materials at its China pilot plant, aiming to start production in February 2026 with customer samples planned for later in the year. The project is co-funded by strategic partner Taza Metal Technologies, reducing capital risk and accelerating development.

ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.

Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its Vision-MR Diagnostic Catheter, paving the way for commercial sales in the US electrophysiology market.